<DOC>
	<DOCNO>NCT00137839</DOCNO>
	<brief_summary>The purpose trial figure effect ( good bad ) investigational drug agent call Tarceva ( erlotinib ; OSI-774 ) woman previously untreated adenocarcinoma .</brief_summary>
	<brief_title>Erlotinib Women With Previously Untreated Adenocarcinoma Lung</brief_title>
	<detailed_description>Patients start take Tarceva daily mouth Day 1 continue take medication daily home , participation study end . Every 28 day ( one cycle ) patient take Tarceva , examine outpatient clinic ( blood test physical examination ) doctor determine continue take Tarceva . After every two cycle treatment ( every 8 week ) standard radiological testing ( CT scan , MRIs , and/or x-ray ) cancer site ( ) do assess response Tarceva treatment . While patient study end study , patient undergo blood urine test , medical history evaluation , physical exam include measure vital sign ( blood pressure , heart rate , temperature , respiration ) , bone scan , tumor biopsy sample , various radiological test monitor cancer patient health . The length time study depend upon cancer respond Tarceva whether patient experience unacceptable side effect .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Female Diagnosis adenocarcinoma lung Patient least one core biopsy tumor Must willing undergo epidermal growth factor receptor ( EGFR ) mutation test tumor Stage IV IIIB nonsmall cell lung cancer Nonsmoker former smoker . Nonsmoker define person smoke 100 less cigarette lifetime former smoker define person quit smoke one year ago . Three week since last radiation therapy Three week since last major surgery Must least able walk capable take care although unable carry work activity Life expectancy 8 week Blood test show kidney , liver bone marrow work adequately Women childbearing potential must agree use adequate contraception prior study entry entire time enrol study Prior exposure Tarceva ( OSI774 , erlotinib ) Uncontrolled central nervous system problem Prior chemotherapy regimen Difficulty swallow A disease disorder interfere ability digest absorb food Incomplete heal previous oncologic major surgery Significant medical history unstable medical condition heart failure , active infection , uncontrolled high blood pressure Pregnant breast feed A medical condition could make unsafe patient participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Tarceva</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Advanced Lung Cancer</keyword>
</DOC>